Spolidorio LC, Spolidorio DM, Massucato EM, Neppelenbroek KH,
Campanha NH, Sanches MH.Oral health in renal transplant
recipients administered cyclosporin A or Tacrolimus (FK506).
Oral Dis. 2006 May;12(3):309-14.
Department of Physiology and Pathology, São Paulo State
University, São Paulo, Brazil.
lcs@foar.unesp.br
OBJECTIVE: The aim of this study was to determine the oral
status of renal transplant recipients receiving cyclosporin A (CsA)
or tacrolimus (FK-506) as immunosuppressant. SUBJECTS AND
METHODS: A total of 88 renal transplant recipients receiving CsA
(63 men and 25 women, mean age 51.4 years) and 67 receiving
FK-506 (57 men and 10 women, mean age 33.5 years) were included
in the study. Donor type, histocompatibility, cold ischemia time
and prior delayed graft function were similar between the two
groups. Demographics and pharmacological data were recorded for
all subjects. RESULTS: The results demonstrated that CsA caused
a greater number of oral diseases. A greater number of gingival
overgrowth was present in patients treated with CsA. However,
the combined use with calcium channel blockers increased the
gingival overgrowth number. The occurrence of candida in saliva
was observed in 80 renal recipients treated with CsA and 20
treated with FK-506. The presence of squamous oral carcinoma (n
= 3) and herpes simplex (n = 10) was observed in patients
treated with CsA. These alterations were not observed in renal
recipients treated with FK-506. CONCLUSIONS: Renal recipients
constitute a high-risk group for oral diseases, as they are
immunocompromised. However, the FK-506 regime appears to
ameliorate this effect, compared with CsA. Adequate pre- and
post-transplant oral health care is recommended for these
subjects, irrespective of the time interval for which the drug
is administered.
PMID: 16700742 |
